Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Expected to Announce Earnings of -$0.14 Per Share

Analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Arrowhead Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.16). Arrowhead Pharmaceuticals reported earnings of $0.21 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 166.7%. The firm is expected to announce its next earnings report on Monday, August 3rd.

According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full-year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.80) to $1.10. For the next financial year, analysts forecast that the company will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.59) to $0.48. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.09). Arrowhead Pharmaceuticals had a return on equity of 2.61% and a net margin of 6.86%. The business had revenue of $23.53 million for the quarter, compared to the consensus estimate of $21.90 million.

Several analysts recently weighed in on ARWR shares. BidaskClub raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 25th. ValuEngine cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 1st. Royal Bank of Canada started coverage on Arrowhead Pharmaceuticals in a report on Tuesday, May 12th. They set an “outperform” rating and a $62.00 price target for the company. Cantor Fitzgerald reissued a “buy” rating and set a $58.00 price target (down from $60.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, May 8th. Finally, Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a report on Tuesday, March 17th. They set a “neutral” rating and a $45.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $62.00.

NASDAQ:ARWR traded down $0.16 during mid-day trading on Tuesday, hitting $42.44. 12,744 shares of the stock were exchanged, compared to its average volume of 1,257,007. The stock has a market capitalization of $4.27 billion, a price-to-earnings ratio of 471.05 and a beta of 1.76. The firm’s 50-day simple moving average is $35.66 and its 200 day simple moving average is $41.10. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.90 and a current ratio of 5.90. Arrowhead Pharmaceuticals has a fifty-two week low of $19.51 and a fifty-two week high of $73.72.

In other news, COO Bruce D. Given sold 23,515 shares of the business’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $40.00, for a total transaction of $940,600.00. Following the completion of the transaction, the chief operating officer now owns 862,793 shares of the company’s stock, valued at approximately $34,511,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $38.81, for a total value of $3,881,000.00. Following the transaction, the chief executive officer now directly owns 2,605,260 shares of the company’s stock, valued at approximately $101,110,140.60. The disclosure for this sale can be found here. Insiders sold a total of 184,815 shares of company stock valued at $7,045,730 over the last ninety days. Insiders own 4.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its position in Arrowhead Pharmaceuticals by 0.6% during the 1st quarter. BlackRock Inc. now owns 12,431,618 shares of the biotechnology company’s stock worth $357,658,000 after acquiring an additional 70,660 shares during the last quarter. State Street Corp grew its position in Arrowhead Pharmaceuticals by 4.1% during the 1st quarter. State Street Corp now owns 4,294,674 shares of the biotechnology company’s stock worth $123,558,000 after acquiring an additional 170,204 shares during the last quarter. Geode Capital Management LLC grew its position in Arrowhead Pharmaceuticals by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 1,515,643 shares of the biotechnology company’s stock worth $43,605,000 after acquiring an additional 83,282 shares during the last quarter. Bank of New York Mellon Corp grew its position in Arrowhead Pharmaceuticals by 0.3% during the 1st quarter. Bank of New York Mellon Corp now owns 1,065,598 shares of the biotechnology company’s stock worth $30,658,000 after acquiring an additional 2,797 shares during the last quarter. Finally, Norges Bank bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $66,233,000. 64.26% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Recommended Story: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.